Works matching IS 00215155 AND DT 2023 AND VI 67 AND IP 3
Results: 14
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Epidemiological investigation of the status of myopia in children and adolescents in Fujian Province in 2020.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 335, doi. 10.1007/s10384-023-00991-y
- By:
- Publication type:
- Article
Postoperative residual vertical deviation affects quality of life in Asian patients with thyroid-associated ophthalmopathy (Graves ophthalmopathy).
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 326, doi. 10.1007/s10384-023-00990-z
- By:
- Publication type:
- Article
Prevalence and severity of diabetic retinopathy at first presentation to vitreoretinal services in Bhutan: a 3-year national study.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 287, doi. 10.1007/s10384-023-00989-6
- By:
- Publication type:
- Article
Orientation of the intermediate-vision zone of rotationally asymmetric multifocal intraocular lenses and photic phenomena.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 318, doi. 10.1007/s10384-023-00988-7
- By:
- Publication type:
- Article
Evaluation of the lamina cribrosa in different stages of diabetic retinopathy.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 280, doi. 10.1007/s10384-023-00987-8
- By:
- Publication type:
- Article
A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 346, doi. 10.1007/s10384-023-00986-9
- By:
- Publication type:
- Article
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 301, doi. 10.1007/s10384-023-00985-w
- By:
- Publication type:
- Article
Correction to: The association of subjective vision with objectively measured intensity-specific physical activity and bout-specific sedentary behavior among community-dwelling older adults in Japan.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 361, doi. 10.1007/s10384-023-00984-x
- By:
- Publication type:
- Article
A novel instrument to determine hue discrimination.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 353, doi. 10.1007/s10384-023-00983-y
- By:
- Publication type:
- Article
Intereye comparison of visual field progression in eyes with open-angle glaucoma.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 312, doi. 10.1007/s10384-023-00982-z
- By:
- Publication type:
- Article
Impact of local COVID-19 alert levels on rhegmatogenous retinal detachment.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 255, doi. 10.1007/s10384-023-00980-1
- By:
- Publication type:
- Article
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 264, doi. 10.1007/s10384-023-00979-8
- By:
- Publication type:
- Article
Practical treatment options for persistent central serous chorioretinopathy and early visual and anatomical outcomes.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 3, p. 295, doi. 10.1007/s10384-023-00978-9
- By:
- Publication type:
- Article